Adverum Biotechnologies to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
05 Settembre 2023 - 10:05PM
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage
company that aims to establish gene therapy as a new standard of
care for highly prevalent ocular diseases, today announced that
Linda Rubinstein, chief financial officer of Adverum
Biotechnologies, will present at the H.C. Wainwright 25th Annual
Global Investment Conference on Tuesday, September 12, 2023.
The on-demand webcast corporate presentation may be accessed
under Events and Presentations in the Investors section of
Adverum’s website. A replay of the webcast will be available on the
website for 90 days following the presentation.
About Adverum BiotechnologiesAdverum
Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that
aims to establish gene therapy as a new standard of care for highly
prevalent ocular diseases with the aspiration of developing
functional cures to restore vision and prevent blindness.
Leveraging the capabilities of its proprietary intravitreal (IVT)
platform, Adverum is developing durable, single-administration
therapies, designed to be delivered in physicians’ offices, to
eliminate the need for frequent ocular injections to treat these
diseases. Adverum is evaluating its novel gene therapy
candidate, ixoberogene soroparvovec (Ixo-vec, formerly
referred to as ADVM-022), as a one-time, IVT injection for patients
with neovascular or wet age-related macular degeneration.
Additionally, by overcoming the challenges associated with current
treatment paradigms for debilitating ocular diseases, Adverum
aspires to transform the standard of care, preserve vision, and
create a profound societal impact around the globe. For more
information, please visit www.adverum.com.
Corporate, Investor and Media InquiriesAnand
ReddiVice President, Head of Corporate Strategy, External Affairs
and EngagementAdverum Biotechnologies, Inc.T:
650-649-1358E: areddi@adverum.com
Grafico Azioni Adverum Biotechnologies (NASDAQ:ADVM)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Adverum Biotechnologies (NASDAQ:ADVM)
Storico
Da Giu 2023 a Giu 2024